Cryosurgery as Additional Treatment in Tenosynovial Giant Cell Tumors

Table 1

Demographics, previous recurrences, and detailed description of treatments received before or in combination with additional cryosurgery.

Patient ID	Sex	Age (at time of surgery)	Localized/diffuse	Previous recurrences	Follow-up before cryosurgery (years)	All treatments received
						1st	2nd	3rd	4th
Knee
1	F	61	Dt-GCT	3	6.3	SE	SE	tSE	tSE + cryo + EBRT
2	M	58	Dt-GCT	2	9.7	Yt	SE	tSE + cryo + EBRT
3	F	46	Dt-GCT	2	3.2	SE	SE	SE + cryo
4	M	51	Dt-GCT	0	0.3	tSE + cryo
5	F	25	Dt-GCT	1	3.0	tSE	SE + cryo
6	F	49	Dt-GCT	0	0.1	SE + cryo
7	M	31	Dt-GCT	2	4.9	tSE	SE	SE + cryo
8	F	31	Dt-GCT	0	0.0	tSE + cryo
Hip
9	M	44	Dt-GCT	2	0.5	tSE	SE	SE + THA + cryo
10	F	20	Dt-GCT	2	4.0	SE	Yt	SE + THA + cryo
Ankle
11	M	34	Dt-GCT	0	0.0	SE + cryo
Elbow
12	F	21	Lt-GCT	0	0.7	SE + cryo

F: female, M: male, SE: surgical synovectomy, tSE: two-stage synovectomy (anterior and posterior compartment of the knee in two separate procedures), Yt: yttrium radiosynovectomy, EBRT: external beam radiation therapy, cryo: cryosurgery, follow-up before cryosurgery: the time from diagnose until the use of cryosurgery in years, and THA: total hip arthroplasty.